Not currently recruiting at UCSD
NL-201 in Patients With Relapsed or Refractory Cancer
a study on Solid Tumor
Solid Tumor Advanced Solid Tumor Cancer NL-201 NL201-101 Phase 1 Immunotherapy Cytokine Pembrolizumab Keytruda IL-2 IL-15 Neoplasms Pembrolizumab Injection [Keytruda]
Lead Scientist at UCSD
- Gregory Daniels, MD, PhD
Dr. Daniels coordinates our clinical program in melanoma. His own research involves understanding the link between autoimmunity and tumor immunity in developing more effective and less toxic vaccines and immune stimulatory approaches for patients with melanoma.
- accepting new patients at some sites,
but this study is not currently recruiting here
- Start Date
- Completion Date
- Neoleukin Therapeutics, Inc.
- Phase 1 Solid Tumor Research Study
- Study Type
- Expecting 252 study participants
- Last Updated